vs
Side-by-side financial comparison of AMREP CORP. (AXR) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $14.6M, roughly 1.3× AMREP CORP.). SCYNEXIS INC runs the higher net margin — 65.7% vs 21.6%, a 44.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 93.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -13.6%).
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
AXR vs SCYX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $18.6M |
| Net Profit | $3.1M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 20.6% | 56.3% |
| Net Margin | 21.6% | 65.7% |
| Revenue YoY | 93.8% | 1808.5% |
| Net Profit YoY | 338.9% | 376.5% |
| EPS (diluted) | $0.58 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $18.6M | ||
| Q3 25 | $17.9M | $334.0K | ||
| Q2 25 | $11.2M | $1.4M | ||
| Q1 25 | $7.5M | $257.0K | ||
| Q4 24 | $11.9M | $977.0K | ||
| Q3 24 | $19.1M | $660.0K | ||
| Q2 24 | $19.5M | $736.0K |
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $12.3M | ||
| Q3 25 | $4.7M | $-8.6M | ||
| Q2 25 | $3.9M | $-6.9M | ||
| Q1 25 | $717.0K | $-5.4M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | $-2.8M | ||
| Q2 24 | $4.1M | $-14.5M |
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | 56.3% | ||
| Q3 25 | 34.4% | -2516.5% | ||
| Q2 25 | 31.7% | -701.0% | ||
| Q1 25 | 5.7% | -3350.2% | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 26.1% | -1563.6% | ||
| Q2 24 | 23.9% | -1255.0% |
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | 65.7% | ||
| Q3 25 | 26.3% | -2572.2% | ||
| Q2 25 | 34.8% | -504.8% | ||
| Q1 25 | 9.5% | -2097.7% | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 21.3% | -425.5% | ||
| Q2 24 | 21.2% | -1964.4% |
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $0.25 | ||
| Q3 25 | $0.87 | $-0.17 | ||
| Q2 25 | $0.73 | $-0.14 | ||
| Q1 25 | $0.13 | $-0.11 | ||
| Q4 24 | $0.75 | — | ||
| Q3 24 | $0.76 | $-0.06 | ||
| Q2 24 | $0.77 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0M | $40.0M |
| Total DebtLower is stronger | $21.0K | — |
| Stockholders' EquityBook value | $139.4M | $49.4M |
| Total Assets | $143.9M | $59.0M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $40.0M | ||
| Q3 25 | $48.9M | $37.9M | ||
| Q2 25 | $39.5M | $44.8M | ||
| Q1 25 | $36.9M | $40.6M | ||
| Q4 24 | $40.1M | $59.3M | ||
| Q3 24 | $40.4M | $68.8M | ||
| Q2 24 | $29.7M | $73.0M |
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $49.4M | ||
| Q3 25 | $134.7M | $36.4M | ||
| Q2 25 | $130.0M | $44.5M | ||
| Q1 25 | $126.0M | $50.5M | ||
| Q4 24 | $125.1M | $55.1M | ||
| Q3 24 | $122.2M | $58.5M | ||
| Q2 24 | $118.0M | $60.4M |
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $59.0M | ||
| Q3 25 | $140.7M | $51.1M | ||
| Q2 25 | $133.8M | $60.7M | ||
| Q1 25 | $128.9M | $67.9M | ||
| Q4 24 | $129.1M | $90.6M | ||
| Q3 24 | $127.0M | $99.0M | ||
| Q2 24 | $122.8M | $107.8M |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.4M | $18.4M |
| Free Cash FlowOCF − Capex | $5.4M | — |
| FCF MarginFCF / Revenue | 37.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.72× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $20.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $18.4M | ||
| Q3 25 | $9.5M | $-8.7M | ||
| Q2 25 | $10.2M | $-7.5M | ||
| Q1 25 | $-3.2M | $-7.5M | ||
| Q4 24 | $-182.0K | $-24.0M | ||
| Q3 24 | $10.7M | $765.0K | ||
| Q2 24 | $10.7M | $-10.9M |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $-3.3M | — | ||
| Q4 24 | $-268.0K | — | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $10.3M | — |
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 86.4% | — | ||
| Q1 25 | -43.4% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 52.5% | — |
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 2.3% | — |
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | 1.50× | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXR
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
